Hyperthermia and Serotonin: The Quest for a "Better Cyproheptadine".

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Hyperthermia, Induced* ; Hypothermia* ; Serotonin Syndrome* ; TRPM Cation Channels*; Animals ; Antidotes ; Cyproheptadine/pharmacology ; Hyperthermia ; Serotonin/pharmacology

Fine temperature control is essential in homeothermic animals. Both hyper- and hypothermia can have deleterious effects. Multiple, efficient and partly redundant mechanisms of adjusting the body temperature to the value set by the internal thermostat exist. The neural circuitry of temperature control and the neurotransmitters involved are reviewed. The GABAergic inhibitory output from the brain thermostat in the preoptic area POA to subaltern neural circuitry of temperature control (Nucleus Raphe Dorsalis and Nucleus Raphe Pallidus) is a function of the balance between the (opposite) effects mediated by the transient receptor potential receptor TRPM2 and EP3 prostaglandin receptors. Activation of TRPM2-expressing neurons in POA favors hypothermia, while inhibition has the opposite effect. Conversely, EP3 receptors induce elevation in body temperature. Activation of EP3-expressing neurons in POA results in hyperthermia, while inhibition has the opposite effect. Agonists at TRPM2 and/or antagonists at EP3 could be beneficial in hyperthermia control. Activity of the neural circuitry of temperature control is modulated by a variety of 5-HT receptors. Based on the theoretical model presented the "ideal" antidote against serotonin syndrome hyperthermia appears to be an antagonist at the 5-HT receptor subtypes 2, 4 and 6 and an agonist at the receptor subtypes 1, 3 and 7. Very broadly speaking, such a profile translates in a sympatholytic effect. While a compound with such an ideal profile is presently not available, better matches than the conventional antidote cyproheptadine (used off-label in severe serotonin syndrome cases) appear to be possible and need to be identified.

Am J Physiol Regul Integr Comp Physiol. 2004 May;286(5):R832-7. (PMID: 14742306)
Br J Pharmacol. 2012 Nov;167(6):1232-43. (PMID: 22646516)
Br J Pharmacol. 2003 Jun;139(4):705-14. (PMID: 12812993)
Am J Physiol Regul Integr Comp Physiol. 2005 Apr;288(4):R909-18. (PMID: 15550616)
J Gen Physiol. 2015 Jun;145(6):485-7. (PMID: 25964430)
Br J Pharmacol. 2000 Jun;130(3):539-48. (PMID: 10821781)
Biol Psychiatry. 2005 Apr 15;57(8):918-25. (PMID: 15820713)
Clin Pharmacol Ther. 1995 Mar;57(3):349-55. (PMID: 7697953)
J Integr Neurosci. 2021 Mar 30;20(1):247-254. (PMID: 33834710)
Life Sci. 1996;59(2):PL37-40. (PMID: 8699917)
Exp Diabetes Res. 2010;2010:686734. (PMID: 21403818)
Pharmacol Ther. 2013 May;138(2):272-84. (PMID: 23356979)
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1375-80. (PMID: 12529502)
Br J Pharmacol. 2008 Mar;153(6):1324-30. (PMID: 18204483)
J Physiol. 2003 Oct 1;552(Pt 1):303-14. (PMID: 12909675)
J Psychopharmacol. 1999;13(1):100-9. (PMID: 10221364)
ACS Chem Neurosci. 2015 Jul 15;6(7):1241-7. (PMID: 25837696)
Biomolecules. 2021 Dec 20;11(12):. (PMID: 34944557)
Radiat Res. 1997 Jun;147(6):741-6. (PMID: 9189174)
Pflugers Arch. 2005 Oct;451(1):204-11. (PMID: 15895246)
J Pharmacol Exp Ther. 2019 Feb;368(2):246-254. (PMID: 30523061)
Neuroscience. 2010 Feb 3;165(3):984-95. (PMID: 19895871)
Sci STKE. 2001 Jul 10;2001(90):re1. (PMID: 11752662)
Exp Physiol. 2005 Mar;90(2):175-81. (PMID: 15604109)
Neuropsychopharmacology. 2006 Jan;31(1):101-11. (PMID: 15920501)
J Biol Chem. 2004 Aug 20;279(34):35741-8. (PMID: 15194687)
Am J Case Rep. 2016 May 23;17:347-51. (PMID: 27210537)
Front Neurosci. 2020 Jul 16;14:629. (PMID: 32765206)
Eur J Pharmacol. 2004 Apr 12;489(3):207-13. (PMID: 15087245)
Neuropharmacology. 2000 Aug 23;39(11):2006-16. (PMID: 10963744)
Temperature (Austin). 2016 Nov 10;4(1):21-23. (PMID: 28349092)
Eur J Pharmacol. 2004 Mar 8;487(1-3):125-32. (PMID: 15033384)
Pflugers Arch. 2018 May;470(5):809-822. (PMID: 29374307)
Eur J Pharmacol. 2019 Jan 5;842:255-261. (PMID: 30412729)
J Gen Physiol. 2015 May;145(5):419-30. (PMID: 25918360)
Nat Neurosci. 2007 Sep;10(9):1131-3. (PMID: 17676060)
Redox Biol. 2016 Apr;7:1-7. (PMID: 26609559)
Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3176-81. (PMID: 24569808)
Br J Pharmacol. 2011 Apr;162(8):1757-69. (PMID: 21198543)
Neuropharmacology. 2003 Jun;44(8):1031-7. (PMID: 12763096)
J Chem Neuroanat. 1997 Jun;13(1):1-21. (PMID: 9271192)
J Clin Med Res. 2009 Jun;1(2):72-80. (PMID: 22505971)
Neuropharmacology. 2020 Oct 15;177:108155. (PMID: 32522572)
Science. 2008 Jul 4;321(5885):130-3. (PMID: 18599790)
Front Pharmacol. 2015 Jul 21;6:143. (PMID: 26257650)
Science. 2016 Sep 23;353(6306):1393-1398. (PMID: 27562954)
Neuropharmacology. 2011 Dec;61(8):1360-5. (PMID: 21884711)
Front Endocrinol (Lausanne). 2018 Aug 07;9:447. (PMID: 30131768)
Eur J Neurosci. 2002 Sep;16(5):817-22. (PMID: 12372017)
Expert Opin Investig Drugs. 2018 Jun;27(6):523-533. (PMID: 29848076)
Hiroshima J Med Sci. 1989 Dec;38(4):173-81. (PMID: 2637245)
J Cardiovasc Pharmacol. 1990;15 Suppl 7:S75-85. (PMID: 1702490)
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jun 8;92:127-132. (PMID: 30611837)
Trends Pharmacol Sci. 2004 Sep;25(9):481-6. (PMID: 15559250)
Cancer Res. 1998 Apr 1;58(7):1515-20. (PMID: 9537257)
Front Pharmacol. 2020 Nov 30;11:580289. (PMID: 33328986)
Trends Pharmacol Sci. 2008 Sep;29(9):472-81. (PMID: 19086344)
J Pharmacol Exp Ther. 2007 Nov;323(2):477-87. (PMID: 17702902)
J Neurosci. 2006 Mar 29;26(13):3423-33. (PMID: 16571749)
Antioxidants (Basel). 2021 Aug 03;10(8):. (PMID: 34439491)
J Anal Toxicol. 2018 Apr 1;42(3):149-156. (PMID: 29244076)
Am J Physiol Regul Integr Comp Physiol. 2021 Dec 1;321(6):R938-R950. (PMID: 34704845)
Genes Dev. 2017 Jan 15;31(2):101-126. (PMID: 28202539)
Eur J Neurosci. 2006 Jul;24(2):535-46. (PMID: 16836640)
Eur J Neurosci. 2006 Aug;24(4):1053-62. (PMID: 16930432)
Neurosci Lett. 2009 Nov 6;465(1):50-4. (PMID: 19735696)

Keywords: 5-HT receptors; cyproheptadine; dopamine; malignant neuroleptic syndrome; serotonin syndrome

0 (Antidotes)
0 (TRPM Cation Channels)
2YHB6175DO (Cyproheptadine)
333DO1RDJY (Serotonin)

Date Created: 20220325 Date Completed: 20220408 Latest Revision: 20220408

20240628

PMC8952796

10.3390/ijms23063365

35328784